Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Elderly
NCT02553343Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2015
- Primary completion
- Apr 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of influenza vaccine in influenza (4 arms), sponsored by Sanofi. Primary endpoints: Solicited injection site and systemic events, unsolicited adverse events and serious adverse events and Hemagglutination inhibition (HAI) antibody titers at Day 28. Started Sep 2015; status: completed.
02
Drugs
influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02553343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02553343.